Royalty Report: Drugs, Drug Discovery, Molecular – Collection: 203348

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Drug Discovery
  • Molecular
  • Diagnostic
  • Therapeutic
  • Disease
  • Proteins
  • Cancer
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203348

License Grant
The Parties enter into an agreement for Licensor to design and synthesize glucokinase activators (GKAs) based on the lead molecules provided by Licensee and input obtained from the in vitro and in vivo testing of the molecules to be synthesized by Licensor as GKAs.

Licensee shall provide lead molecules that will be used by Licensor to design and synthesize molecules optimized for activation of the Target.

The Parties shall use commercially reasonable efforts to design and synthesize molecules that are optimized for activation of the Target Molecules based on the lead molecules provided by Licensee.

Licensor shall provide the structure of each such Molecule and any information about the Molecule that is available.

Licensor shall promptly assign to Licensee all such related intellectual property.

License Property
The Product means a pharmaceutical product that contains a Molecule,  that is conceived as a part of the Project,  considered by the Joint Committee for synthesis as a Molecule, and which either could have been reduced to practice by Licensor but for the Project ending or is reduced to practice by Licensee, the  Compound.
Field of Use
Licensor shall have the right to use the Molecules for screening purposes, except against the Target.  The target that is to be activated is glucokinase.

Glucokinase is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Glucokinase occurs in cells in the liver and pancreas of humans and most other vertebrates.

IPSCIO Record ID: 271607

License Grant
The purpose of this Materials Transfer and Testing Agreement, is among other things, the research of original material made up of plants, plant matter, and plant extracts, the Plant Materials, to identify bioactive molecules contained in these Plant Materials which may lead to the commercial production of bioactive molecules.

The Licensee’s research and development efforts with Licensor, a non-profit institute,  have been centered on selective screening of certain natural product for the purpose of identifying extracts and further isolating molecules that may be effective as potential anti-inflammatory, neuro-protective and oxidative stress relieving molecules.

License Property
To date, the Licensee has screened one plant source and has fractionated extracts to determine its neuroprotective activity.  This plant source and extracted material has shown a high degree of neuroprotectant factor in the face of ethanol and ammonium toxicity in neuronal cell cultures.  Research activity has led to the discovery of novel molecules with biological activity and to the formation of new life sciences companies that will seek to commercialize discoveries centered on natural products.
Field of Use
The field of use is to develop methods and use of this material in the treatment of neurodegenerative diseases.

IPSCIO Record ID: 291205

License Grant
By this agreement, Licensor will use its DirectedDiversity Technology to compute a chemical descriptor matrix to describe and map the compounds for which Licensee provides data.  Licensor also will develop a Structure Activity Relationship model based on this descriptor matrix for Hits.  The license during the research period is exclusive.

Licensor grants a worldwide, exclusive license, with right to sublicense, in the Field under such patent to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited under a written agreement with a third party from granting such an exclusive license. In the event that Licensor is so contractually prohibited from granting such an exclusive license, Licensor shall grant to Licensee as broad a scope of license as it is permitted (for example, a non-exclusive license) and Licensor shall use its reasonable best efforts to negotiate with such third party to remove such contractual prohibition so as to allow Licensor to grant Licensee the foregoing exclusive license under such Licensor Patents.

For the Unblocking License Grant – Licensor grants a worldwide, nonexclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensor Compounds, Derivative Compounds, and Licensed Products, under any Licensor patent rights which would otherwise be infringed by Licensee but for this license.

License Property
Licensor is engaged in discovery research for a variety of biologically active compounds and the development of technologies to facilitate such research, and has patented systems for generating chemical compounds having desired pharmaceutical properties.

DirectedDiversity Technology means Licensor Patents and proprietary know-how that relate to generating and utilizing a DirectedDiversity Chemical Library.

DirectedDiversity(R) Chemi-Informatic Technology uses proprietary computer algorithms to design, select and iteratively refine combinatorial libraries of novel, small-molecule drugs based on screening hits obtained from  Licensor or other screening libraries, target-protein 3D structures, or pharmacophore models derived from lead compounds.

Active Compound means a Licensor Compound or Derivative Compound that has been formally selected by Licensee for preclinical and/or clinical development.

Field of Use
Field means human and animal therapeutic and diagnostic imaging uses of compounds against or acting through Targets. The Field for any particular Target will include all therapeutic indications for compounds acting through Targets, including but not limited to the indications identified in the Research Plan.

Licensee is engaged in research and development of human therapeutic products.  The purpose of this collaboration is to identify qualified lead compounds active against selected targets and suitable for medicinal chemistry optimization that may be developed and commercialized by Licensee.

IPSCIO Record ID: 306496

License Grant
The Licensee was granted an exclusive license to certain Intellectual Property.
License Property
Licensor is the exclusive licensing agent for a University and representing Mayo Clinic’s interests in certain patents and intellectual property rights.  The Intellectual Property encompasses the inhibition of tumor growth using compounds that inhibit QSOX1 enzymatic activity and, specifically, to anti-neoplastic compounds targeting QSOX1 (the parent molecule referred to as SBI-183).

The enzyme Quiescin Sulfhydryl Oxidase 1 (QSOX1) is a master regulator of extracellular matrix remodeling, and its overexpression by tumor cells.  Overexpression of QSOX1 has been unambiguously linked to promoting tumor invasion and metastasis.  It has been discovered that a small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo.

This license is to technology relating to SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis.  Small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo. Through its medicinal chemistry efforts the Licensee synthesized multiple structural analogs of SBI-183 and unveiled SPX-1009 lead compound that demonstrated ten-fold improvement in suppressing invasion and metastasis in several cancer models.

SBI-183 enhances the activity of cytotoxic drugs in vitro.

Field of Use
Licensee was formed to develop a unique biomarker for cancer (QSOX1) as well as cancer diagnostic and therapeutic products based on QSOX1.  Licensee is a research and development company that aims to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis.

IPSCIO Record ID: 248009

License Grant
At Licensees option, The German Licensor shall grant a non-exclusive license in the Territory, under Licensors rights in Licensor Returned QT Know-How and Returned QT Patent Rights to the extent necessary
– to research, develop, make and use any or all of the following in connection with the use of the Returned QT to discover or develop Small Molecule Drugs
(1) the Licensor Configured Assay that embodies or is based on a Returned QT, together with the standard operating procedures and reagents necessary,  to use such Licensor Configured Assay for such purpose;
(2) if a Second Stage QT is designated as a Returned QT, the most promising lead structure under development by Licensor, and the optimization history of such lead structure and the data pertinent to critical optimization decisions that relate to such lead structure, the Second Stage Information, including without limitation, information on the major structural templates that were evaluated by Licensor and relevant SAR data; and
(3) if a Third Stage QT is designated as a Returned QT, the most promising lead structure under development by Licensor, and the optimization history of such lead structure and the data pertinent to critical optimization decisions that relate to such lead structure, the Third Stage Information, including without limitation, related SAR data, related pharmacological data, including toxicology and ADME information, and information related to chemical synthesis, provided, however, that, in the case of a Second Stage QT or a Third Stage QT, Licensor shall not be obligated to grant any such license with respect to the most promising lead structure if such lead structure is under development by Licensor as a Development Candidate or later stage drug candidate outside of the Licensor Development Program, in which event Licensor shall be obligated to grant such a license with respect to the next most promising lead structure that is not a Development Candidate or later stage drug candidate outside of the Licensor Development Program, and,
– to make, have made, import, use, have used, offer for sale, sell and have sold Small Molecule Drugs that are discovered or developed by Licensee through the use of Returned QTs.

This agreement includes exclusive and non-exclusive grants back to Licensor from Licensee.

License Property
Licensor is engaged in the business of conducting research in the field of human genomics, an objective of which is to discover potential biological targets and assays for use in drug discovery.

Cell-Based Assay means a Licensor Configured Assay that uses a QT incorporated in a cell or presented on the surface of a cell, as distinct from a biochemical assay in which the QT is assayed in a cell-free context.

Qualified Target or QT means a target for Small Molecule drug discovery identified or developed in the course of the Target Discovery Program that has all of the following characteristics
– is a Druggable Target that is a complete coding sequence of a human gene;
– has a Disease/Therapeutic Hypothesis;
– is either a Novel Protein, or fill Unrecognized Protein, or a Druggable Target that is otherwise approved by the Licensor Program Director as a Qualified Target; and
– the use of such target in the manner contemplated in the Research Plan would not, at the time of its identification or annotation in the Target Discovery Program, infringe one or more claims of an issued patent in the country in which such use of the target is expected to occur, unless such target is otherwise approved by the Licensor Program Director.

Non-Exclusive QT means a QT that has a Disease/Therapeutic Hypothesis in both a CFA and Non-CFA and that is designated by Licensee as a Non-Exclusive QT within seven (7) business days after such QT is entered into the QT Pool and a Licensee-Designated NonCFA means one Non-CFA that is associated, on the basis of a Disease/Therapeutic Hypothesis, with a QT, as designated by Licensee at the time such QT is designated a Non-Exclusive QT by Millennium.

Field of Use
Field means therapeutic and prophylactic treatment of all human diseases and conditions.  This agreement is to identify and develop small molecule drugs for the treatment of certain human diseases and conditions.

IPSCIO Record ID: 367275

License Grant
With Respect to Library Compounds, Licensor grants a worldwide, non-exclusive license, under Licensor Intellectual Property, to use Library Compounds and Library Compound Information for research purposes in the discovery of Hits to Licensee Targets, performing Hit-to-Lead Chemistry Programs and Lead Optimization Programs and in the Development of Royalty-Bearing Products that contain Library Compounds, which license shall include the right to use Synthetic Methodology and Pathways solely to synthesize Library Compounds which have been identified as Hits and Library Compounds structurally related thereto, and Licensee Analogs that derive from such Library Compounds, for the purpose of performing Drug Discovery Programs.

With Respect to Analogs, Licensor grants a worldwide, perpetual, non-exclusive license, under Licensor Intellectual Property, to use Analogs and Licensee Analog Information in the discovery of Hits to Licensee Targets, performing Hit-to-Lead Chemistry Programs and Lead Optimization Programs and in the Development of Royalty-Bearing Products and Non-Royalty-Bearing Products that contain Analogs, which license shall include the right to use Synthetic Methodology and Pathways solely to synthesize Analogs.

License Property
Licensor Controls certain technology for the creation of large numbers of complex, natural-compound-like compounds for the purpose of screening biological targets to identify potential human therapeutics.

Target shall mean a protein or polypeptide, which is involved in a biological process as well as orthologs thereof and all isoforms or polymorphisms, including single nucleotide polymorphisms, alleles, and other naturally-occurring or synthetic derivatives, including, without limitation, insertions, additions, deletions, fragments and splice variants thereof and nucleic acid sequences encoding any of the above that is configured into one or more assays for screening, including, but not limited to, in vitro assays and phenotypic or pathway screens, cell-based or in vivo assays, or used for structure-based compound design.

Library Compound shall mean a compound that Licensor delivered pursuant to the Prior Agreement.

Library Compound Information shall mean structural, process or other information relating to a Library Compound.

Library Compound Structure Information shall mean documentation of the molecular formula and molecular structure of each Library Compound.

Hit shall mean a Library Compound or an Analog that is confirmed as active against a Licensee Target, or for which computational data is generated which predicts activity, which is subsequently confirmed as active against a Licensee Target.

A Licensee Analog is designed, discovered or synthesized by Licensee in the course of a Drug Discovery Program.

Synthetic Methodology and Pathways shall mean, with respect to a Library Compound, the synthetic scheme that Licensor used to synthesize the Library Compound,

Field of Use
The technology is used for the purpose of screening biological targets to identify potential human therapeutics.

IPSCIO Record ID: 230755

License Grant
The parties entered into a research collaboration to allow Licensee and Licensor to identify Prototype Compounds active against selected targets that may be developed and commercialized by Licensee.
License Property
Target means a protein against which Hits are identified and Prototype Compounds are to be optimized in the Research Program. Targets, as defined herein, shall also include Replacement Targets once such targets become Targets.

Prototype Compound means a compound discovered using information obtained from a Hit in the course of Prototype Compound Generation having a dissociation constant less than or equal to 0.5 µM as determined in a dose response experiment and which demonstrates a desired activity against a Target in a molecular or cellular functional assay. Prototype Compounds will have pharmaceutically acceptable properties as determined by the Licensee prior to initiation of Prototype Compound Generation and confirmed in a series of in vitro assays, including p450 metabolism, p450 inhibition, logP, logD, pKa, Caco-2 permeability and solubility. Prototype Compounds will be identified as Prototype Compounds by the Licensee within thirty (30) days of delivery of data from such in vitro assays. For purposes of clarity, the Licensee may, at its discretion, select a compound as a Prototype Compound even if such compound does not meet the criteria set forth above.

Prototype Compound Generation means a program for discovering Prototype Compounds using information obtained from Hits, and iterative rounds of chemistry and the Licensor Synthetically Accessible Library to make Focused Libraries for rescreening using ThermoFluor(R) Technology against such Target.

Licensor Synthetically Accessible Library means Licensors virtual compound library as it exists from time to time from which Licensor Probe Libraries have been selected, and from which Focused Libraries will be selected.

Licensor Probe Library means the sample compound library or any subset thereof, comprised of proprietary and non-proprietary compounds which are owned or Controlled by Licensor or to the extent not encumbered by a bona fide third party interest, that have been synthesized for the purposes of fulfilling Licensors obligations under this Agreement, which is used for the screening of Targets using ThermoFluor(R) Technology for the purpose of identification of Hits, Prototype Compounds, or Active Compounds. While the individual non-proprietary compounds in the Licensor Probe Library are not proprietary, the collection itself, and the list, as a whole, of non-proprietary compounds included in the collection, are the 'Confidential Information' of Licensor.

Active Compound means a compound(s) claimed by a Valid Claim of a Licensor Patent, Joint Patent or Research Program Patent Right.

ThermoFluor(R) Technology means the technology described in
(a)   the Licensor Patents identified below, and (b) associated proprietary Licensor Know-how used to evaluate ligand binding parameters of Hits, Prototype Compounds, and Active Compounds.

6,020,141 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
6,036,920 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization
6,291,191 – Microplate Thermal Shift Assay for Ligand Development and Multi-variable Protein Chemistry Optimization

DirectedDiversity(R)Technology means the technology described in
(a) the Licensor Patents identified below, and (b) associated proprietary Licensor know-how used to identify Hits, Prototype Compounds, and Active Compounds.

5,463,564 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
5,574,656 – System and Method of Automatically Generating Chemical Compounds with Desired Properties
5,684,711 – System and Method of Automatically Generating Chemical Compounds with Desired Properties

Field of Use
Field means the research, development and commercialization of compounds for use in therapeutic, prophylactic and diagnostic products in humans or animals. The Field shall specifically exclude the field of treatment with, research on, and/or development of drugs whose principal aim is to treat or cure of infectious disease in humans; provided however, after March 7, 2003, the Field shall not have any such exclusion.

IPSCIO Record ID: 223145

License Grant
Licensor grants to Licensee such rights that it has to grant a worldwide, exclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, under any Patent Rights owned by Licensor that would otherwise be infringed by Licensee but for this license, including Research Program Patent Rights, and under the Know-how developed by Licensee relating to the Licensed Products, including the Research Program Know-how.

This DiscoverWorksâ„¢ agreement is a research and development collaboration to identify Initial Hits, Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds active against selected targets, and suitable, if required, for medicinal chemistry optimization, that may be developed and commercialized.

License Property
The patents include System and method of automatically generating chemical compounds with desired properties, and, Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization.

Licensed Product means any commercial product containing an Active Compound as an active ingredient.

Active Compound means a Program Lead Compound or a Pre-Clinical Lead Compound identified in the course of the Research Program, or compound further optimized from such a Program Lead Compound or a Pre-Clinical Lead Compound.

Chemical Optimization means the design, synthesis and identification of Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds using DiscoverWorksâ„¢ Technology and other technologies.

DiscoverWorks™ Technology means DirectedDiversity® Technology and ThermoFluor® Technology.

DirectedDiversity(R) Technology means the descriptions, figures and claims of the Patent Rights and associated proprietary Licensor Know-how used to identify potential therapeutic compounds.

ThermoFluor® Technology means the Patent Rights and associated proprietary Licensor Know-how used to evaluate ligand-binding parameters.

Field of Use
The Field means the research, development and commercialization of chemical compounds for use in therapeutic and diagnostic products, except for use in the treatment or cure of Hepatitis C Virus through March 7, 2003 in humans.

IPSCIO Record ID: 203296

License Grant
For the Non-Exclusive Research License to Licensors Base Technology,  Licensor grants a non-exclusive, world-wide license under the Base Technology and Collaboration Technology to conduct research and Development activities with respect to Targets, Hits, Research Compounds, Lead Compounds and IND Candidates pursuant to the Research Plan.   Licensor also grants the right to sublicense or transfer the rights granted to Licensee under the Collaboration Technology to  Affiliates; and to Third Parties.
License Property
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

Gene Expression Modulation by Small-molecules (GEMS) is PTC’s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.

Field of Use
The Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.